BrightInsight Inks Enterprise Agreement with CSL Behring for Digital Health Solutions Across Brand Portfolio
Following success of Hizentra App, CSL Behring and BrightInsight expand partnership to build apps for rare disease medicines across the...
Healthcare
QHSLab, Inc. Projects a $7.5 Billion Addressable Market for its Integrated Service Program (ISP) Digital Health Solution Designed For Primary Care
This forecast is based on estimates generated through a recent pilot program and scaled through approximately 250,000 independent primary care...
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
– Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast...
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing...
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
Financing led by Wellington Management with participation from other leading healthcare fundsCARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX...
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa...
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered...
iCAD to Present at HLTH 2022 With Google
Google invites iCAD’s President and CEO, Stacey Stevens, to be a featured speaker in the Google Health Theater Room on...
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million...
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development Investigational...
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
Completed enrollment in the Phase 1 study with novel, broad-spectrum antiviral PB2 candidate CC-42344 for the treatment of pandemic and...
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
Robust two-year X-ray results of medial joint space width (mJSW) and significant pain response in patients with earlier disease highlight...
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
THE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the...
Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to...
Stereotaxis Reports 2022 Third Quarter Financial Results
ST. LOUIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for...
Zealand Pharma Announces Financial Results for the First Nine Months of 2022
Company announcement No. 51 / 2022 Zealand Pharma Announces Financial Results for the First Nine Months of 2022 Copenhagen, Denmark...
HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratificationSouthlake, Texas, Nov. 10, 2022...